GlaxoSmithKline commenced a cash tender offer for Nuvalent on Wednesday, offering $28.00 per share for the clinical-stage biopharmaceutical company. The deal values Nuvalent's equity at approximately $2.1 billion and marks GSK's largest oncology acquisition since the $1.9 billion Sierra Oncology purchase in 2022. Nuvalent closed Tuesday at $27.89, suggesting the market had priced in closure before the formal announcement.
Nuvalent develops selective tyrosine kinase inhibitors targeting ROS1 and ALK mutations in non-small cell lung cancer. The company's lead asset, zidesamtinib, is in Phase III trials for ROS1-positive NSCLC with data readouts expected in 2026. A second candidate, NVL-655, targets ALK-positive disease and sits in Phase II. Neither drug is approved. GSK gains two shots at precision oncology indications where Pfizer's Lorbrena and Novartis's Zykadia command existing market share, but where resistance mutations create segmentation opportunities. The tender offer is conditioned on a minimum of 50.1% of Nuvalent shares tendering by the expiration date, currently set for May 14, 2025, with standard regulatory clearances.
The acquisition fills a gap in GSK's oncology pipeline that has relied heavily on Jemperli, a PD-1 inhibitor approved for endometrial cancer, which generated $506 million in 2024 sales. Jemperli faces biosimilar pressure beginning in 2029 when key patents expire. Zidesamtinib's Phase III data, if positive, would position GSK to file for approval in late 2026 or early 2027, providing a narrow window to establish commercial infrastructure before Jemperli's erosion accelerates. The deal also reflects GSK's pivot away from consumer health post-Haleon spin and toward higher-margin specialty therapeutics. CEO Emma Walmsley has allocated $8 billion in M&A capacity through 2026 under the updated capital allocation framework disclosed in March 2024. This tender consumes roughly 26% of that budget.
The structure matters. GSK chose a tender offer rather than a negotiated merger, signaling confidence in shareholder acceptance without protracted board negotiations. Nuvalent's board has not issued a formal recommendation, though the $28 price represents a 25% premium to the thirty-day volume-weighted average price before acquisition rumors surfaced in early April. The absence of a breakup fee or go-shop provision suggests GSK locked terms quietly. Antitrust risk is minimal; neither company has overlapping commercial products, and the Hart-Scott-Rodino waiting period should clear within 30 days. The financing is internal. GSK held $8.2 billion in cash and equivalents as of December 31, 2024, and maintains a net debt position of $18.1 billion, comfortably within its stated leverage target of 2.5x EBITDA.
Allocators should track three events: Nuvalent's Q1 2025 earnings call in early May, where management will address the tender formally; the HSR clearance announcement, expected by mid-May; and GSK's Q2 earnings in late July, where integration costs and revised oncology pipeline guidance will surface. If zidesamtinib's Phase III data in 2026 shows non-inferiority to Lorbrena with a superior safety profile, GSK positions for a $600-800 million peak sales asset in a segmented indication. If the data disappoint, the write-down begins in 2027.
The deal is not a pivot. It is ammunition for a portfolio manager who accepted that Jemperli alone cannot carry oncology margin expectations past 2028.